Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Gabriel Tremblay,1 David Chandiwana,2 Mike Dolph,1 Jaclyn Hearnden,1 Anna Forsythe,1 Mauricio Monaco2 1Purple Squirrel Economics, New York, NY, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA Background: Ribociclib (RIBO) and palbociclib (PALBO), combined with letrozole (LET), have...

Full description

Bibliographic Details
Main Authors:	Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-05-01
Series:	Cancer Management and Research
Subjects:	breast cancer indirect treatment comparison matching-adjusted indirect treatment comparison ribociclib palbociclib
Online Access:	https://www.dovepress.com/matching-adjusted-indirect-treatment-comparison-of-ribociclib-and-palb-peer-reviewed-article-CMAR

Similar Items

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
by: David G. Maloney, et al.
Published: (2021-09-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01)

Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs
by: Francisco Javier Parrondo-García, et al.
Published: (2021-03-01)

Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes
by: Yawen Jiang, et al.
Published: (2020-09-01)

Multiple treatment and indirect treatment comparisons: An overview of network meta-analysis
by: Nidhi Bhatnagar, et al.
Published: (2014-01-01)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

Indirect comparison of efficacy between different antibiotic prophylaxis against the intracranial infection after craniotomy
by: Yulong Cao, et al.
Published: (2020-07-01)

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer
by: Mahtani RL, et al.
Published: (2019-01-01)

Statistical Methods for Aggregation of Indirect Information
by: Han, Simeng
Published: (2014)

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
by: Tremblay G, et al.
Published: (2019-09-01)

How compare biologics applied for rheumatic disorders?
by: Eugeniusz J. Kucharz
Published: (2014-06-01)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
by: Ilario Giovanni Rapposelli, et al.
Published: (2021-05-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

INDIRECT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT
by: S. V. Goryajnov, et al.
Published: (2012-04-01)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
by: Valentina Rossi, et al.
Published: (2019-10-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
by: Adil Daud, et al.
Published: (2017-01-01)

Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis
by: M. Galván-Banqueri, et al.
Published: (2015-01-01)

Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011)

Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011)

Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011)

Novel P2Y12 Receptor Antagonists - Prasugrel and Ticagrelor. Systematic Review, Indirect Comparison to Clopidogrel in Cardiovascular Disease, Design of a Randomized Controlled Trial
by: Steiner-Boeker, Sabine
Published: (2011)

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
by: Balazs Halmos, et al.
Published: (2020-12-01)

Ribociclib in 1st line HR+ breast cancer treatment
by: L G Zhukova, et al.
Published: (2018-06-01)

Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience
by: Boér K, et al.
Published: (2021-07-01)

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
by: Xinmei Li, et al.
Published: (2020-04-01)

Using indirect comparisons in pharmacoeconomic examination
by: Yu. E. Balykina, et al.
Published: (2015-03-01)

An investigation of the impact of using different methods for network meta-analysis: a protocol for an empirical evaluation
by: Amalia (Emily) Karahalios, et al.
Published: (2017-06-01)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
by: Edessa D, et al.
Published: (2017-12-01)

Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons
by: Song Fujian, et al.
Published: (2012-09-01)

PRACTICAL ASPECTS OF ADMINISTERING CYCLIN-DEPENDENT KINASES INHIBITORS: EFFICACY AND TOLERABILITY
by: E. V. Artamonova
Published: (2018-04-01)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
by: Fournier, Marie, et al.
Published: (2014-10-01)

Evaluation of Bioequivalence of Generic Imatinib Products and Generic Tacrolimus Products Based on Indirect Comparison of the Results of Their Bioequivalence Studies
by: D. V. Goryachev, et al.
Published: (2019-09-01)

The number needed to treat and relevant between-trial comparisons of competing interventions
by: Jansen JP, et al.
Published: (2018-12-01)

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
by: Jiajie Lu, et al.
Published: (2021-05-01)

A simulation study to compare different estimation approaches for network meta-analysis and corresponding methods to evaluate the consistency assumption
by: Corinna Kiefer, et al.
Published: (2020-02-01)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
by: B. Porte, et al.
Published: (2020-12-01)

Cannot write session to /tmp/vufind_sessions/sess_ign9ugbbol15a1hu3amtblfjbb